Program
avatrombopag
Also written as “E5501”, “Avatrombopag” and “Avatrombopag 20 mg Oral Tablet”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic, led by 2 companies.
Drug pageAvatrombopag: every studyAll 52 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 180 open or running | phase 3since Sep 13, 2011 | Feb 27, 2007 | none ahead |
| Swedish Orphan Biovitrum | 71 open or running | phase 4since Nov 11, 2020 | Oct 27, 2017 | Jun 30, 2028phase 3 · NCT07786922 |
Also a collaborator on its studies: CMIC Co, Ltd. Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Swedish Orphan Biovitrum only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2017First study: phase 3 study in ThrombocytopeniaFirst studyNCT03326843 · 4 enrolled · United States
- Mar 7, 2018Phase 3 study in ThrombocytopeniaNCT03471078 · 122 enrolled · United States, China, Hungary and more
- Aug 14, 2020Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT04516967 · 75 enrolled · United States, France, Germany and more
- Nov 11, 2020Phase 4 study in Purpura, Thrombocytopenic, IdiopathicNCT04638829 · 60 enrolled · United States
- Sep 8, 2021Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT05046327
- Apr 21, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT05369208 · 19 enrolled · Japan
- Jul 30, 2026Phase 3 study in Anemia, AplasticNCT07786922 · 26 planned
Ahead
- Jun 30, 2028Primary completion: phase 3 study in Anemia, AplasticNCT07786922
TargetBeta
“The maleate salt form of avatrombopag, an orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, ”NCIt, by rule
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eltrombopagrule | GlaxoSmithKline | phase 4 | 49 |
| romiplostimrule | Amgen | phase 4 | 38 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
All 7 Swedish Orphan Biovitrum leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07786922Anemia, Aplastic | 3 | Not yet recruiting | Jun 30, 2028 | 26 |
| NCT05369208Purpura, Thrombocytopenic, Idiopathic · Japan | 3 | Completed | Jan 17, 2024 | 19 |
| NCT05046327Purpura, Thrombocytopenic, Idiopathic | 3 | Withdrawn | Apr 6, 2024 | 0 |
| NCT04638829Purpura, Thrombocytopenic, Idiopathic · United States | 4 | Completed | Jan 3, 2024 | 60 |
| NCT04516967Purpura, Thrombocytopenic, Idiopathic · United States, France, Germany and more | 3 | Completed | Nov 8, 2023 | 75 |
| NCT03471078Thrombocytopenia · United States, China, Hungary and more | 3 | Completed | Aug 28, 2020 | 122 |
| NCT03326843Thrombocytopenia · United States | 3 | Terminated | Feb 25, 2019 | 4 |
How it is read
Names in the registry
- “E5501”, 9 entries
- “Avatrombopag”, 8 entries
- “Avatrombopag 20 mg Oral Tablet”, 2 entries
- “Avatrombopag Oral Tablet”, 2 entries
- “avatrombopag”, 2 entries
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 11 studies
- Thrombocytopenia, 8 studies
- Anemia, Aplastic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.